Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
Ghassan K. Abou‐Alfa(Memorial Sloan Kettering Cancer Center), Bruno Sangro(Clinica Universidad de Navarra), Tu Van Dao(Vietnam National Children's Hospital), В. В. Бредер, Robin Kate Kelley(UCSF Helen Diller Family Comprehensive Cancer Center), Masatoshi Kudo(Kindai University), Alejandra Negro(AstraZeneca (Japan)), Stephen L. Chan(Chinese University of Hong Kong), Enrico N. De Toni(LMU Klinikum), Junji Furuse(Kanagawa Prefectural Hospital Organization), Kabir Mody(Mayo Clinic in Florida), Lorenza Rimassa(Humanitas University), Alexander Vasilyev(Russian Railways), Vincent C. Tam(University of Calgary), Wattana Sukeepaisarnjaroen(Khon Kaen University), Philip He(AstraZeneca (Japan)), George Lau(Humanity & Health), Yoon‐Koo Kang(Ulsan College), Satheesh Chiradoni Thungappa(Sri Venkateshwaraa Medical College Hospital and Research Centre), Alexandra Heurgué(Hôpital Robert-Debré)
Cited by 398
Related Papers
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2016|2.7k
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
|New England Journal of Medicine|2005|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k